Search research articles
Contact Us
Filters
Showing results (11-20 of 173) with videos related to
Page
of 18
Sort By:
Diagnostics (Basel, Switzerland)
|
June 24, 2022
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool
Sara Galimberti, Serena Balducci, Francesca Guerrini, et al.
Pharmacogenomics
|
June 9, 2017
Should CYP2D6 be genotyped when treating with tamoxifen?
Marzia Del Re, Eleonora Rofi, Valentina Citi, et al.
Pharmacological Research
|
March 8, 2021
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice
Stefano Fogli, Sara Galimberti, Veronica Gori, et al.
Pharmacogenomics
|
November 25, 2016
Should CYP2D6 be genotyped when treating with tamoxifen?
Marzia Del Re, Eleonora Rofi, Valentina Citi, et al.
Expert Review of Molecular Diagnostics
|
April 15, 2014
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Marzia Del Re, Enrico Vasile, Alfredo Falcone, et al.
Pharmacological Research
|
November 27, 2015
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema
Stefano Fogli, Selene Mogavero, Colin Gerard Egan, et al.
Epigenomics
|
August 2, 2016
Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications
Antonello Di Paolo, Marzia Del Re, Iacopo Petrini, et al.
Eye (London, England)
|
February 6, 2018
Clinical pharmacology of intravitreal anti-VEGF drugs
Stefano Fogli, Marzia Del Re, Eleonora Rofi, et al.
Cancer Treatment Reviews
|
April 30, 2026
Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumours
Nicola Fazio, Francesca Spada, Lavinia Benini, et al.
Journal of Theoretical Biology
|
November 10, 2015
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
Sheema Sameen, Roberto Barbuti, Paolo Milazzo, et al.
Page
of 18
Search research articles
Search
Showing results (11-20 of 173) with videos related to
Sort By:
Page
of 18
Diagnostics (Basel, Switzerland)
|
June 24, 2022
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool
Sara Galimberti, Serena Balducci, Francesca Guerrini, et al.
Pharmacogenomics
|
June 9, 2017
Should CYP2D6 be genotyped when treating with tamoxifen?
Marzia Del Re, Eleonora Rofi, Valentina Citi, et al.
Pharmacological Research
|
March 8, 2021
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice
Stefano Fogli, Sara Galimberti, Veronica Gori, et al.
Pharmacogenomics
|
November 25, 2016
Should CYP2D6 be genotyped when treating with tamoxifen?
Marzia Del Re, Eleonora Rofi, Valentina Citi, et al.
Expert Review of Molecular Diagnostics
|
April 15, 2014
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Marzia Del Re, Enrico Vasile, Alfredo Falcone, et al.
Pharmacological Research
|
November 27, 2015
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema
Stefano Fogli, Selene Mogavero, Colin Gerard Egan, et al.
Epigenomics
|
August 2, 2016
Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications
Antonello Di Paolo, Marzia Del Re, Iacopo Petrini, et al.
Eye (London, England)
|
February 6, 2018
Clinical pharmacology of intravitreal anti-VEGF drugs
Stefano Fogli, Marzia Del Re, Eleonora Rofi, et al.
Cancer Treatment Reviews
|
April 30, 2026
Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumours
Nicola Fazio, Francesca Spada, Lavinia Benini, et al.
Journal of Theoretical Biology
|
November 10, 2015
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
Sheema Sameen, Roberto Barbuti, Paolo Milazzo, et al.
Page
of 18